Clinical Trials in Poland / NCT07428499
Recruiting
Phase 3
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499 · tracked via the Priya Life Science Poland tracker
Condition(s) studied
Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2HAE
Investigational drug(s) / intervention(s)
ADX-324 Dose Level 1ADX-324 Dose Level 2
ADX-324 Dose Level 1: siRNA duplex oligonucleotide
ADX-324 Dose Level 2: siRNA duplex oligonucleotide
Study summary
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Eligibility
Inclusion Criteria:
* Have a documented diagnosis of HAE (Type I or II)
* Completed Study ADX-324-301
* Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)
Exclusion Criteria:
* A negative reaction to study drug in ADX-324-301
Primary outcome measure(s)
- Safety of ADX-324 in Participants with HAE — Month 36
Incidence and severity of treatment-emergent adverse events
Trial sites (48)
| Facility | City | Region | Status |
|---|---|---|---|
| ADARx Clinical Site | Litchfield Park | Arizona | Not Yet Recruiting |
| ADARx Clinical Site | Little Rock | Arkansas | Not Yet Recruiting |
| ADARx Clinical Site | San Diego | California | Not Yet Recruiting |
| ADARx Clinical Site | Walnut Creek | California | Not Yet Recruiting |
| ADARx Clinical Site | Orlando | Florida | Not Yet Recruiting |
| ADARx Clinical Site | Chevy Chase | Maryland | Not Yet Recruiting |
| ADARx Clinical Site | Wheaton | Maryland | Not Yet Recruiting |
| ADARx Clinical Site | Detroit | Michigan | Not Yet Recruiting |
| ADARx Clinical Site | St Louis | Missouri | Not Yet Recruiting |
| ADARx Clinical Site | Las Vegas | Nevada | Recruiting |
| ADARx Clinical Site | New York | New York | Recruiting |
| ADARx Clinical Site | Cincinnati | Ohio | Not Yet Recruiting |
| ADARx Clinical Site | Columbus | Ohio | Not Yet Recruiting |
| ADARx Clinical Site | Toledo | Ohio | Not Yet Recruiting |
| ADARx Clinical Site | Hershey | Pennsylvania | Not Yet Recruiting |
| ADARx Clinical Site | Capital Federal | Buenos Aires | Not Yet Recruiting |
| ADARx Clinical Site | Buenos Aires | Buenos Aires F.D. | Not Yet Recruiting |
| ADARx Clinical Site | Adelaide | South Australia | Not Yet Recruiting |
| ADARx Clinical Site | Vienna | Austria | Not Yet Recruiting |
| ADARx Clinical Site | Edegem | Antwerpen | Not Yet Recruiting |
| ADARx Clinical Site | Sofia | Bulgaria | Not Yet Recruiting |
| ADARx Clinical Site | Edmonton | Alberta | Not Yet Recruiting |
| ADARx Clinical Site | Ottawa | Ontario | Not Yet Recruiting |
| ADARx Clinical Site | Montreal | Quebec | Not Yet Recruiting |
| ADARx Clinical Site | Beijing | China | Not Yet Recruiting |
| ADARx Clinical Site | Harbin | China | Not Yet Recruiting |
| ADARx Clinical Site | Zhengzhou | China | Not Yet Recruiting |
| ADARx Clinical Site | Split | Croatia | Not Yet Recruiting |
| ADARx Clinical Site | Zagreb | Croatia | Not Yet Recruiting |
| ADARx Clinical Site | Hradec Králové | Czechia | Recruiting |
| ADARx Clinical Site | Prague | Czechia | Not Yet Recruiting |
| ADARx Clinical Site | Nice | Alpes-Maritimes | Not Yet Recruiting |
| ADARx Clinical Site | Tours | Indre-et-Loire | Not Yet Recruiting |
| ADARx Clinical Site | Montpellier | France | Not Yet Recruiting |
| ADARx Clinical Site | Paris | France | Not Yet Recruiting |
| ADARx Clinical Site | Tübingen | Baden-Wurttemberg | Not Yet Recruiting |
| ADARx Clinical Site | Hong Kong | Hong Kong | Not Yet Recruiting |
| ADARx Clinical Site | Budapest | Hungary | Not Yet Recruiting |
| ADARx Clinical Site | Ashkelon | Israel | Not Yet Recruiting |
| ADARx Clinical Site | Tel Aviv | Israel | Not Yet Recruiting |
+ 8 more sites — see the full list on the official registry below.
More ADARx Pharmaceuticals, Inc. trials in Poland
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Recruiting
Other trials for the same condition
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Enrolling by invitation
A Study of Navenibart in Participants With Hereditary Angioedema
Active, not recruiting
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
Enrolling by invitation
A Phase 2 in Adult Subjects With Hereditary Angioedema
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07428499 on ClinicalTrials.gov ↗ ← All trials in Poland